Consumption of flavanol-containing cocoa products has been shown to lower blood pressure (BP), but the minimum dose required to reduce BP is not known. This study aimed to examine the effect of three different doses of cocoa flavanols (CF) on 24-h mean arterial BP. Twenty four hour ambulatory BP (24-ABP) monitoring was performed in 32 men and 20 postmenopausal women with untreated mild hypertension (seated clinic BP 4130/ 85 and o160/100 mm Hg). Participants were randomized and instructed to consume daily a reconstituted cocoa beverage containing 33, 372, 712 or 1052 mg day À1 of CF for 6 weeks in a double-blind, parallel comparison. Seated clinic BP and 24-h ABP were measured at 0, 3 and 6 weeks. Seated clinic BP did not change during the study period. There were significant reductions in 24-h systolic (5.3±5.1 mm Hg; P ¼ 0.001), diastolic (3±3.2 mm Hg; P ¼ 0.002) and mean arterial BP (3.8±3.2 mm Hg; P ¼ 0.0004) at the 1052 mg day À1 CF only. No reduction in BP was seen at any other dose. No evidence of doseresponse was seen in this experiment. The highest dose of 1052 mg CF per day was found to significantly lower BP. These results support previous evidence for CF to lower BP, however more research is needed to establish the most effective dose and food matrix.
Introduction
Several intervention studies have reported beneficial effects of consuming cocoa-containing products on blood pressure (BP) [1] [2] [3] [4] [5] and a recent meta-analysis confirmed this effect by demonstrating that the consumption of cocoa-rich foods for 7 or more days has the capacity to lower resting BP in normotensive and mildly hypertensive adults. 6 This effect of cocoa products has been widely attributed to the content of flavanols and procyanidins (oligomeric and polymeric flavanols), which for the purpose of this paper will be included in the term 'cocoa flavanols' (CFs). 7, 8 The recent meta-analysis 6 included five studies that compared the antihypertensive effects of CFrich chocolate with chocolate containing few or no CF. The amount of chocolate consumed daily ranged from 46 to 105 g and provided intakes of CF ranging from 246 to 500 mg day À1 . There was a mean BP reduction of 4.7/2.8 mm Hg (systolic/diastolic). In a subsequent study that was not included in the metaanalysis, Taubert et al. 9 showed that consuming as little as 30 mg of CF per day in 6 g of dark chocolate for 18 weeks was sufficient to lower systolic blood pressure (SBP) by 2.9 mm Hg and diastolic blood pressure (DBP) by 1.9 mm Hg. A more recent metaanalysis by Hooper et al. 10 also reported a net effect in favour of cocoa in the order of 6 mm Hg SBP and 3 mm Hg DBP. Although the potential antihypertensive effect of chocolate consumption is interesting, the high sugar and fat content of chocolate undermines its potential as a health-enhancing food. 11, 12 Concern about delivering CF in a high-sugar and high-fat chocolate food matrix has led to investigations of the potential antihypertensive and other cardiometabolic health benefits of relatively low-fat drinks enriched with CF. In a study that examined the acute effect of consuming a flavanol-rich cocoa beverage, Schroeter et al. 13 demonstrated an increase in flow-mediated dilatation of the brachial artery. Four studies have been conducted examining the longer-term effects of consuming flavanol-rich cocoa beverages on cardiovascular health in various populations. In the first of these, daily consumption of 446 mg of CFs by post-menopausal women for 6 weeks produced a significant improvement in arterial function but no change in BP compared with placebo. 14 In another study, individuals with type II diabetes took 963 mg day À1 for a period of 30 days and also demonstrated improvements in endothelial function but not BP. 15 In a third study in which overweight or obese individuals consumed 902 mg day À1 of flavanols for 12 weeks, there were improvements in endothelial function with modest yet significant reductions in BP (mean arterial pressure (MAP) reduced by 1.2 mm Hg). 16 The fourth study provided approximately 900 mg day À1 of CF to individuals with essential hypertension for 2 weeks. 17 Despite the similarity of this protocol to that by which Grassi et al. 4 showed BP reductions with chocolate, and despite providing almost double the daily dose of CF, there was no change in BP although there was some improvement in endothelial function. The lack of BP change in three of these studies and the relatively small change in the other following chronic consumption of large doses of CF are inconsistent with the results seen in the metaanalysis 6 and subsequent study 9 with flavanol-rich chocolate consumption. These findings suggest that the dose of CF alone does not determine the change in BP, however a number of differences in the design of these studies makes direct comparisons difficult. The studies that have been published to date examined different patient populations (healthy and hypertensive adults in chocolate-based protocols and hypercholesterolaemic, overweight/obese and type II diabetic in non-chocolate protocols), and the type II diabetes study was confounded by participant medications. A further complication with comparison is a lack of consistency in the technique of BP assessment. Most studies have used seated clinic BP assessments with only three studies to date using the preferred technique of ambulatory blood pressure (ABP) monitoring. 3, 4, 18 These three studies used the same protocol of a 15-day crossover study with dark chocolate (delivering approximately 500 mg of CF) or white chocolate (CF free) in three separate subject groups including essential hypertensives and have reported the largest reductions in BP to date. With these factors in mind, a single study evaluating the potential BP-lowering effects of CF in a homogenous patient population using the preferred method of ABP assessment and delivering the CF in a consistent food matrix was warranted. Therefore, the primary aim of this study was to determine the dose-response effect of CF delivered using a flavanol-rich cocoa beverage on 24-h ambulatory MAP in an untreated borderline/mild hypertensive population. Secondary outcomes include clinic BP assessment and additional measures of 24-h ABP.
Materials and methods

Participants
Male and post-menopausal female adults with highnormal BP or untreated mild hypertension (SBP 130-160 mm Hg or DBP 85-100 mm Hg) were recruited by public advertisement. Participants were excluded if they had a known diagnosis of cardiovascular disease (or a history of cardiovascular or cerebrovascular incidents); diabetes (type I or type II) or were taking prescribed anti-diabetic medication; renal failure; were taking BP-lowering medication or supplements that may influence BP (i.e. fish oil, liquorice, polyphenols) in the preceding 3 months, or were likely to do so during the study period; an intolerance to alkaloids (caffeine, theobromine) or dairy; were currently smoking or using nicotine replacement therapy; or had any other medical condition that may have influenced the outcome of the study. 
Eligibility screening
Potential participants were initially screened for eligibility by completing a health and lifestyle questionnaire and undertaking a seated clinic BP assessment. Participants with a seated BP between SBP 130-160 mm Hg or DBP 85-100 mm Hg were enrolled in the study. Enrolled participants returned to the clinic approximately 1 week later to have their BP measured under the same conditions as the initial screening to confirm the presence of high-normal BP or mild hypertension. If they requalified (that is, SBP 130-160 mm Hg or DBP 85-100 mm Hg), they commenced the study protocol. If their BP fell outside these limits they were invited to return for an additional qualifying BP assessment. Participants with screening BP consistently above thresholds for BP (that is, DBP 4100 mm Hg; SBP 4160 mm Hg) were referred to their general physician and not entered into the study.
Protocol outline
Participants were block-matched by the minimization convention 19 on BP, gender, age and body mass index into four treatment groups that were randomized to consume reconstituted cocoa beverages containing 33, 372, 712 or 1052 mg day À1 of CF for 6 weeks in a double-blind, parallel comparison. Randomization of groups was undertaken independently of group minimization procedure by separate staff members of the research centre not otherwise involved with the trial. Trial investigators remained blinded to treatment allocation until after the completion of data analysis. Participants then had body weight assessed and underwent seated clinic BP and 24-h ABP assessments at baseline and were then required to consume a cocoa drink daily for the next 6 weeks. Seated clinic BP and 24-h ABP assessments were repeated after 3 and 6 weeks ( Table 2) .
Cocoa supplements
The cocoa drinks were prepared by participants mixing the contents of three cocoa beverage sachets with 300 ml of water each morning and drinking 30 min before breakfast. The CF composition of the cocoa beverages are provided in Table 1 . Sachets (dry powder-58 g net) were matched for micro and macronutrients, including total energy (mean B910 kJ); saturated fat (mean B1.4 g); sugar (approximate mean B17.5 g); caffeine (mean B43 mg); and theobromine (mean B430 mg).
On all testing days (at 3 and 6 weeks), volunteers were instructed not to consume their cocoa beverage until after testing was completed to eliminate any acute effects of cocoa consumption. All empty sachets were returned at 3 and 6 weeks to monitor compliance. Participants were instructed to report any signs or symptoms of ill health immediately to the researchers and any action that was taken (for example, medication) to identify any potential adverse effect of the intervention. In addition to this, participants were specifically asked at each visit whether any signs or symptoms of ill health had been experienced. All reported events were documented by the researchers in each participant's case report form.
Blood pressure monitoring Seated clinic BP was assessed after sitting quietly for at least 5 min using an automated oscillometric BP monitor (HDI/Pulsewave CR-2000 Cardiovascular Profiler, Hypertension Diagnostics Inc., Eagan, MN, USA) in accordance with the procedures outlined by the Joint National Committee on the Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (VII): US Dept of Health and Human Services. 20 Four consecutive BP readings were taken at 1 min intervals by a single observer. The first reading was discarded and an average of the remaining measurements was taken to determine eligibility for study entry.
For assessment of 24-h ABP, volunteers were fitted with a SpaceLabs ambulatory BP monitor (Model 90217, SpaceLabs Medical, Issaquah, WA, USA) for 24 h. An appropriately sized cuff was placed firmly around the upper non-dominant arm, centred over the brachial artery, with the monitor worn on a waist strap; ABP measurements were recorded at 15 min intervals excepting from 2300-0700 hours (30 min intervals). The cuff and monitor were only removed briefly for bathing and remained in place at all other times during the 24-h recording period. Assessments at baseline, 3 and 6 weeks were carried out on the same day of the week using the same monitor, cuff size and arm. Participants were required to maintain an activity diary during each 24-h ABP period to enable BP values to be related to activities. Recordings of 24-h ABP were used to determine daytime (0700-2300 hours), night time (2300-0700 hours) and 24-h averages for MAP, SBP, DBP and heart rate (HR).
Diet and lifestyle requirements
Volunteers were asked to maintain their normal physical activity patterns and were provided with a list of dietary exclusions to ensure a low-flavanol diet for 1 week before and during the study period. Given the energy content of the beverages (B900 kJ), volunteers were advised on appropriate diet substitutions to avoid increasing total energy intake. To monitor compliance with this request, body weight was measured at each clinic visit.
Statistical analysis
It was estimated that a sample size of 12 subjects per arm would have at least 80% power to detect a statistically significant difference in reduction in MAP between the four treatment groups (allowing for multiple comparisons) using an analysis of variance at the 0.05 significance level. The estimates were based on the assumption of a linear doseresponse effect achieving a 5 mm Hg change in 24-h MAP with the highest dose and a s.d. of 4 mm Hg as indicated by unpublished pilot data. These estimates are supported by the previously reported ABP results with CF consumption (3, 4, 18) .
Baseline characteristics were compared between groups by one-way analysis of variance. Comparison of changes in ABP between treatment groups (that is, CF dose) across time (that is, 3-and 6-week assessments) was performed using repeated measures analysis of covariance using baseline ABP as the covariate. Where analysis of covariance showed a statistically significant main effect, post hoc comparisons (Tukey's HSD) were conducted to 
Results
Participant flow is provided in Figure 1 . In total, 53 volunteers completed the study. One volunteer was excluded because of mild persistent (43 day) gastric symptoms that may have been related to the test beverage. No other adverse events related to the study were reported. Five volunteers withdrew during the study because of personal circumstances unrelated to the study. One volunteer was excluded from the analysis due to non-compliance to the study protocol, leaving 52 volunteers, or n ¼ 12-14 volunteers per arm. Trial withdrawals and exclusions did slightly impact on the success of the minimization process on the matching of groups for the stated baseline parameters, as can be seen in Table 2 . However, no significant between-group differences were seen for the blocking parameters including age (P ¼ 0.45), body mass index (P ¼ 0.28) and BP (SBP P ¼ 0.86; DBP P ¼ 0.45). Compliance with consumption of cocoa supplements was greater than 98% in all groups. Body mass did not change during the intervention (P ¼ 0.48 for treatment Â time). SBP, DBP, MAP or HR for 24-h, night, day and seated clinic measurements for each treatment group are provided in Tables 3-6 . There were no dose Â time interactions for seated clinic BP, but a significant time effect for SBP (P ¼ 0.02) and MAP P ¼ 0.01) was evident. However, there were significant dose Â time effects for 24-h MAP (P ¼ 0.047) and overnight HR (P ¼ 0.041) assessed by ABP monitoring. Analysis of covariance of the change from baseline (week 0) to weeks 3 and 6 (with baseline values as a covariate) revealed a significant effect of dose on 24-h ambulatory SBP (P ¼ 0.019), DBP (P ¼ 0.017) and MAP (P ¼ 0.008) and night ambulatory SBP (P ¼ 0.0006), DBP (P ¼ 0.005) and HR (P ¼ 0.043).
Nested analysis (time nested in dose) revealed significant dose effects for 24-h MAP (P ¼ 0.0004), SBP (0.001) and DBP (P ¼ 0.002); night time MAP (P ¼ 0.01; Figure 3 ) and SBP (P ¼ 0.003) and daytime MAP (P ¼ 0.02; Figure 3 ) and SBP (P ¼ 0.02). Post hoc analysis showed that for the 1052 mg flavanol dose, the reductions in for 24-h MAP (Po0.001), SBP (Po0.02) and DBP (Po0.04) were significantly different from all other doses (refer Figure 2 ). There were no significant effects on HR. Figure 3 displays a consistent reduction in day and night ABP to that seen over the full 24 h, with significant effects observed at a CF level of 1052 mg day À1 .
Discussion
The principal finding of this study was that the regular consumption of flavanol-rich reconstituted cocoa beverages reduced BP in untreated patients with borderline/mild hypertension. This antihypertensive effect was only evident at the highest dose of 1052 mg CF per day, with doses up to and including 712 mg day À1 failing to provide any significant reduction in BP in this study. This is the first study to directly compare the efficacy of differing dose levels of isolated CF. The doses used were on the basis of range of CF levels that have been previously reported to lower BP. These findings suggest that BP can be lowered through the regular consumption of flavanol-rich cocoa beverages, although higher levels of CF may be required than has been observed with consumption of chocolate-based CF-rich products. Although this study provided the highest Figure 1 Consort diagram. *-withdrawn for personal or health reasons not related to study protocol; **-excluded because of gastric symptoms possibly related to cocoa beverage; ***-excluded due to non-compliance to study protocol (deliberate weight loss during intervention period).
Cocoa and blood pressure K Davison et al dose of CF to date, the lack of effect on BP with lower doses is supported by previous studies using a non-chocolate food matrix. Although there was no evidence of a dose-response effect over the doses tested in this trial, it may be the case that the highest dose in this study is on the lower end of a doseresponse curve with this type of CF product. In addition, the maximum potential effect on BP is yet to be determined. Four previous studies have investigated the longer-term effects of consuming flavanol-rich cocoa beverages on BP 14-16 using beverages providing daily flavanol doses ranging from 446 to 964 mg. Of these studies, only one demonstrated a reduction in BP and this was a study that provided one of the highest doses of flavanols (902 mg day À1 ). The finding of this study is in agreement with the outcome of the current study that demonstrated that a high daily flavanol dose is required in order to achieve a reduction in BP. However, these findings are in contrast to those that have examined the BP-lowering effects of CFs delivered in a chocolate food matrix in which antihypertensive effects have been demonstrated with flavanol doses that were reported to be significantly lower than the levels used in the studies with cocoa beverages. A recent metaanalysis 9 that examined the antihypertensive effects of flavanol-rich chocolate found that daily consumption of chocolate providing relatively modest doses of CFs and procyanidins ranging from 246 to 500 mg provided significant reductions in BP. Subsequently, Taubert et al. 9 showed that consuming as little as 30 mg of cocoa polyphenols per day in dark chocolate for 18 weeks was sufficient to lower SBP by 2.9 mm Hg and DBP by 1.9 mm Hg. This latter flavanol dose is similar to the lowest flavanol dose provided in the current study in which no effect on BP was observed. Thus, it appears there may be a discrepancy in the effective dose of flavanols when delivered in a chocolate matrix compared with a beverage mix. A previous bioavailability study showed that there was no difference in the acute increases in plasma or urinary concentrations of flavanols after consumption of chocolate or dry cocoa containing the same quantities of flavanols, 21 and similar bioavailability of CFs from chocolate and other sources is also supported by comparisons from other studies. 1, 13, 21 There has been some debate over the potential for the addition of milk protein to cocoa products to reduce flavanol bioavailability 22 and this would potentially impact on efficacy when consumed in milk drinks. However, other recent studies have not supported any effect of milk on reducing flavanol bioavailability. [22] [23] [24] A noteworthy protocol consideration when comparing the studies using flavanol-rich chocolate and flavanol-rich beverages are the degree of placebo control and blinding. Studies using chocolate have typically used a flavanol-poor white chocolate placebo that limits subject blinding and is not matched for all potentially bioactive nutrients including methylxanthines (3) (4) 9) . The use of flavanol-rich cocoa beverages allows close matching of placebo beverage nutrient composition as well as close matching for colour and flavour to facilitate a double-blinded protocol. [13] [14] [15] [16] propose that the discrepancy between the results seen with dark chocolate and flavanol-rich cocoa beverages may be entirely due to these factors. The robust placebo control and blinding used in this study combined with ABP monitoring provides a superior assessment of the antihypertensive potential of CF to those conducted previously. The mechanism by which CF reduce BP has been largely attributed to their capacity to improve endothelial dilatory function. 8, 25 A number of studies have demonstrated that the regular intake of CFs can improve endothelium-mediated vascular dilatory function, with these improvements being associated with an increased bioavailability of nitric oxide. 2, 4, [25] [26] [27] [28] Recently Taubert et al. 9 established a direct relationship which suggested that the BPlowering effects of CFs were mediated by improved nitric oxide availability when they found a statistically significant correlation between the magnitude of reduction in BP and the magnitude of increase in S-nitrosoglutathione (a marker of nitric oxide availability) after 18 weeks of consuming chocolatecontaining CFs. However, some studies have demonstrated improvements in vascular dilatory function independently of changes in BP, suggesting that other mechanisms might also contribute to the antihypertensive effect. Two recent studies 14, 15 reported a sustained (non-acute) improvement in markers of endothelium-mediated dilatory function without concurrent changes to BP, whereas a third study 16 conducted in our laboratory showed improvement in both parameters but only a modest reduction was seen in BP as endothelium-mediated dilatory function improved by approximately 40%.
The lack of a demonstrable effect of cocoa consumption on seated clinic BP in this study may also reflect the relative lack of sensitivity of this technique compared with ABP monitoring. Seated clinic BP reduced with time independently of flavanol dose, reflecting a habituation effect (regression to the mean) that most likely masked any treatment effect on BP. An habituation effect was not evident with ABP monitoring. In a previous study, we were able to demonstrate a statistically significant reduction in BP with clinic assessments, 16 but the BP assessment protocol in that study was different from that used in this study with clinic BP measured while participants were supine after a longer pre-assessment rest period. In addition, for the previous study, patients with elevated BP were not specifically recruited, which may have reduced the likelihood of a 'white coat' hypertensive effect masking any effect of the cocoa supplement.
A key concern with the consumption of bioactive nutrients for health benefits is the question of potential adverse effects of the other ingredients. In the case of CFs this concern is particularly associated with the high energy and saturated fat content of chocolate. According to high-performance liquid chromatography analysis of flavanol content of various food types, to achieve the effective dose of flavanol seen in this study (1052 mg) would require the daily consumption of 210 g of standard dark chocolate or approximately double this amount of milk chocolate. 29 Given that 210 g of dark chocolate provides 4700 kJ and 35 g of saturated fat, a net health effect may be questionable. 30 This is in contrast to the 914 kJ and 1.4 g of saturated fat provided by the beverage used in this trial. However, depending on the underlying causes of the previously discussed discrepancy between the effect of chocolate and flavanol-rich cocoa beverages on BP, this comparison may not prove valid. It should be noted that the intention of this trial was not to evaluate the use of a flavanol-rich beverage as a potential food supplement, but rather to determine the effect of various doses of CFs on BP.
Ideally, the lowest dose would deliver 0 mg of flavanol; however, this would be not possible with our cocoa-based product without significantly altering the flavour and or consistency of the drink, thereby compromising the treatment blinding. Although Taubert et al. 9 reported an antihypertensive effect of 30 mg CF per day, this has only been seen with a white vs dark chocolate protocol and not with a well-matched control, so interpretation of these data are subject to the limitations listed above. Moreover, others have failed to show effects on BP of considerably higher doses of isolated CF. 14, 15 Other concerns regarding the 33 mg dose results in this study relate to the lower age and body mass index and greater proportion of males in this group. Although care was taken to avoid this in the blocking process, with the relatively small subject numbers per treatment arm, small numbers of participant attrition can disrupt this balance. It could be argued that this may reduce the potential responsiveness of the control group; however, the lack of BP reduction seen at the two intermediate doses suggests that this has not influenced the overall results. In addition, the differences seen in body mass index and age were not statistically significant and the most important variable (BP) remained well matched across the four groups. The final limitation was the lack of explicit assessment of the effectiveness of the blinding protocol. The close matching of the cocoa products implies successful blinding; however, these results could have been strengthened by assessing this.
In summary, this study provides the most robust assessment of the effects of CFs on BP to date. A significant antihypertensive effect of daily CF intake was observed at the highest dose of 1052 mg flavanols per day with no BP-lowering effect seen at the lower doses. This study supports the potential for CFs to lower BP, but further research is required to determine the extent of antihypertensive benefit that can be achieved with different dietary sources and doses of flavanols in various cardiovascular pathologies.
